Sector News

Sorry, Endo. Valeant’s back on top with $173-per-share Salix bid

March 16, 2015
Life sciences
So you thought you could wrestle Salix away from Valeant, Endo? The Canadian pharma has a message for you: Think again.
 
CEO J. Michael Pearson’s deal machine upped its original $158 per share offer for the North Carolina company to $173 per share in cash, or about $15.8 billion, forcing Endo to drop out of the running. With Salix on board with the new price, Valeant expects to close the deal on April 1, it said Monday.
 
While Endo last week offered $175 per share, its bid comprised cash and stock–1.4607 shares of its stock and $45 per Salix share–meaning the deal’s value would fluctuate with Endo’s stock price. Valeant’s counterbid removed that risk, Pearson said in a statement.
 
“This revised offer provides Salix shareholders with all cash at a significant premium and the certainty to close by April 1,” Pearson said in a statement.
 
Of course, that April 1 closing date isn’t exactly “certain”–and Valeant built in some conditions for that exact reason. If Salix shareholders don’t satisfy the minimum tender offer by April 8, Valeant’s price will drop back down to $158 per share, it said.
 
And if Endo had managed to lure Salix away? Valeant raised its breakup fee along with its bid, meaning Salix would have been on the hook for $100 million if it had walked.
 
Valeant’s new proposal builds on its late-February pact to buy Salix, a deal Pearson hailed as a chance to penetrate the fast-growing, “undertreated and underserved” GI market. In inking that accord, Quebec-based Valeant reportedly beat out Shire ($SHPG), rumored to be readying a bid at the time, and Endo, whose advances Salix had already turned down more than once.
 
But Endo–helmed by former Valeant president Rajiv De Silva, an avid dealmaker in his own right–until now refused to go away. Last week, De Silva touted a “substantially superior” transaction that came along with a seat for Salix on the combined company’s board.
 
“While we are disappointed with this outcome, we have been and will continue to be disciplined in our approach to potential acquisitions,” De Silva said in a statement Monday.
 
Meanwhile, reports say Valeant turned to top shareholders to finance its increased offer, including Bill Ackman’s hedge fund Pershing Square. Late last year, Pearson and Ackman failed in their joint effort to buy Allergan, losing the months-long hostile pursuit to white knight Actavis. Earlier this month, Pershing took a nearly 5% stake in Valeant, saying it has no plans to shake things up there.
 
By Carly Helfand
 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).